Clinical trial
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic…
NCT00005876 · Astex Pharmaceuticals, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00005876 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery |
| Official title | A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | rubitecan |
| Start date | Apr 1, 2000 |
| First posted | Dec 17, 2003 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: